Intensity Therapeutics (INTS) Operating Leases (2023 - 2026)

Intensity Therapeutics (INTS) has 4 years of Operating Leases data on file, last reported at $70000.0 in Q1 2026.

• Quarterly Operating Leases fell 46.56% year-over-year to $70000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70000.0 (down 46.56% YoY) and the FY2025 annual result came in at $79000.0, down 42.75% from the prior year.
• Operating Leases declined to $70000.0 in Q1 2026, from $79000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $158000.0 in Q4 2023 to a low of $70000.0 in Q1 2026.
• A 4-year average of $122131.5 and a median of $131000.0 in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases increased 0.81% — and 2026, when it plunged 46.56%.
• Tracing INTS's Operating Leases over 4 years: stood at $158000.0 in 2023, then decreased by 12.66% to $138000.0 in 2024, then sank by 42.75% to $79000.0 in 2025, then slipped by 11.39% to $70000.0 in 2026.
• The last three Operating Leases figures came in at $70000.0 (Q1 2026), $79000.0 (Q4 2025), and $87000.0 (Q3 2025), per Business Quant data.